AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in this application.

Listing of Claims:

1-14. (previously cancelled)

15. (currently amended) A method of reducing solid tumor volume in an animal or human in need thereof, comprising **inhibiting** ~~administering to said animal or human a therapeutically effective amount in unit dosage form of a composition comprising at least one secretase inhibitor that inhibits γ-secretase or β-secretase~~ **γ-secretase activity and** ~~processing of amyloid precursor protein (APP), said amount being effective to inhibit~~ angiogenesis ~~and~~ **in said tumor, independent of Notch cleavage,** to reduce solid tumor volume in said animal or human.

16-20. (previously cancelled)

21. (currently amended) The method of claim 15, wherein the **method comprises administering a γ-secretase inhibitor selected from the group consisting of L-685,458, DAPT, DAPM, and JLK-6** ~~route of administration of the composition~~ to the animal or human **[[**is**]]** via **a parenteral, oral, or topical** ~~parenteral, oral or intraperitoneal~~ **route of** administration.

22. (currently amended) The method of claim 21, wherein the parenteral route of administration is selected from the group consisting of intravenous; intramuscular; interstitial; infra-arterial; subcutaneous; intraocular; intracranial; intraventricular; intrasynovial; **and** transepithelial **routes**~~, including transdermal, pulmonary via~~

~~inhalation, ophthalmic, sublingual and buccal; topical, including ophthalmic, dermal, ocular, rectal, and nasal inhalation via insufflation or nebulization~~.

23. (currently amended) The method of claim ~~15~~ **21**, wherein the ~~composition~~ **γ-secretase inhibitor** is administered in a unit dosage form orally in the form of hard or soft shell gelatin capsules, tablets, troches, sachets, lozenges, elixirs, suspensions, syrups, wafers, powders, granules, solutions or emulsions.

24. (currently amended) The method of claim ~~22~~ **21**, wherein the **topical** route of administration is nasal inhalation, which inhalation is by an aerosol, an atomizer or a nebulizer.

25-26. (previously cancelled)

27. (cancelled)

28. (cancelled)

29. (previously cancelled)

30. (cancelled)

31. (currently amended) The method of claim ~~30~~ **21**, wherein the ~~dipeptide protease~~ γ-secretase inhibitor is selected from the group consisting of DAPT and DAPM.

32-38. (cancelled)

39-61. (previously cancelled)

62. (previously presented) The method of claim 15, wherein the solid tumor is a human malignant brain tumor.

63. (currently amended) The method of claim 62, wherein the human **malignant** brain tumor is a glioblastoma.

64. (previously presented) The method of claim 15, wherein the solid tumor is a human lung adenocarcinoma tumor.

65. (previously presented) The method of claim 15, wherein the solid tumor is a human malignant breast tumor.

66. (previously presented) The method of claim 15, wherein the solid tumor is a human malignant colon tumor.

67. (previously presented) The method of claim 15, wherein the solid tumor is a human malignant kidney tumor.

68. (previously presented) The method of claim 15, wherein the solid tumor is a human malignant bladder tumor.

69. (previously presented) The method of claim 15, wherein the solid tumor is a human malignant head tumor.

70. (previously presented) The method of claim 15, wherein the solid tumor is a human malignant neck tumor.

71. (currently amended) The method of claim ~~15~~ **21**, wherein said **γ-secretase inhibitor is administered in a** composition further ~~comprises~~ **comprising** a pharmaceutically acceptable carrier or diluent.

72. (currently amended) The method of claim ~~28~~ **21**, wherein the ~~aspartyl protease transition-state~~ γ-secretase inhibitor is L-685,458.

73. (previously presented) The method of claim 15, wherein said method is a method for reducing solid tumor volume in a human in need thereof.

74. (new) **The method of claim 22, wherein said transepithelial route of administration is selected from transdermal, pulmonary via inhalation, opthalmic, sublingual, and buccal routes.**

75. (new) **The method of claim 21, wherein said topical route of administration is selected from opthalmic, dermal, ocular, rectal, and nasal inhalation via insufflation or nebulization routes.**

76. (new) **The method of claim 21, wherein the γ-secretase inhibitor is DAPT.**

77. (new) **The method of claim 21, wherein the γ-secretase inhibitor is DAPM.**

78. (new) **The method of claim 21, wherein the γ-secretase inhibitor is JLK-6.**

79. (new) **The method of claim 15, wherein γ-secretase activity and angiogenesis are inhibited without Notch cleavage.**